JNJ vs DGX
By Alex · Tickerpine
Johnson & Johnson vs Quest Diagnostics Incorporated, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | DGX |
|---|---|---|
| Price | $260.86 | $237.77 |
| Market cap | $628.65B | $26.24B |
| P/E ratio | 30.3 | 25.2 |
| ROE | 25.74% | 14.60% |
| Profit margin | 21.48% | 9.19% |
| Revenue growth | 6.60% | 10.20% |
| Dividend yield | 2.05% | 1.45% |
| Beta | 0.23 | 0.55 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs DGX in plain English
- JNJ is the bigger company — about 24.0× the market cap of DGX.
- DGX is cheaper on earnings (P/E 25.2 vs 30.3).
- JNJ earns a higher return on equity (26% vs 15%).
- DGX is growing revenue faster (10% vs 7%).
- JNJ has the higher dividend yield (2.05% vs 1.45%).
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
DGX return calculator
See what $1,000 in Quest Diagnostics Incorporated would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.